LexDanaLexDanabeta
Inventor

Wylie W. Vale, Jr.

Inventor
La Jolla, CA, US

Overview

119→
Patents
1978–2017
Patent span
Human necessities
Primary field (CPC A)

Patents· 119 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides31%
A61KPreparations for medical, dental or toiletry purposes29%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests15%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations12%
C12NMicroorganisms or enzymes3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A01KAnimal husbandry2%
A23KFodder2%
C07CAcyclic or carbocyclic compounds1%
C07DHeterocyclic compounds1%
PatentTitleYear
9,572,866'Urocortin 2 analogs and uses thereof'20179,555,032'Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling'20179,546,210'Cripto antagonism of activin and TGF-b signaling'20179,388,229'Urocortin-III and uses thereof'20169,314,506'Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors'20168,669,092'Urocortin-III and uses thereof'20148,445,425'Urocortin-III and uses thereof'20138,258,279'Isolated nucleic acids encoding soluble corticotropin releasing factor receptor type 2 (sCRFR2) polypeptides'20128,084,413'Urocortin-III and uses thereof'20118,044,025'Urocortin proteins and uses thereof'20117,893,213'Antibodies to activin receptor'20117,869,958'Structure-based modulators of B1 G-protein coupled receptors'20117,851,588'CRFR1 selective ligands'20107,820,620'Cripto antagonism of activin and TGF-b signaling'20107,815,905'Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors'20107,674,463'Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist'20107,638,607'Urocortin proteins and uses thereof'20097,575,751'Activin-A mutants'20097,507,794'Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2)'20097,488,865'Urocortin-deficient mice and uses thereof'20097,459,427'Urocortin-III and uses thereof'20087,455,839'Method of inhibiting the formation of inhibin/betaglycan complexes with an anti-betaglycan antibody'20087,358,225'Cloning and recombinant production of CRF receptor(s)'20087,223,846'Urocortin proteins and uses thereof'20077,141,546'CRFR2 selective ligands'20066,953,838'Urocortin-III and uses thereof'20056,838,274'Urocortin proteins and uses thereof'20056,835,544'Methods of screening for compounds that bind to activin receptor'20046,812,210'Urocortin-III and uses thereof'20046,692,744'Betaglycan as an inhibin receptor and uses thereof'20046,638,905'Cloning and recombinant production of CFR receptor(s)'20036,495,343'Cloning and recombinant production of CRF receptor(s)'20026,482,608'Cloning and recombinant production of CRF receptor(S)'20026,399,315'Screening assays using cloned CRF receptors'20026,353,152'Corticotropin releasing factor receptor 2 deficient mice and uses thereof'20026,214,797'Urocortin peptides, nucleic acid encoding same methods for using same'20016,166,287'Corticotropin-releasing factor overproducing transgenic mice'20006,162,896'Recombinant vertebrate activin receptors'20006,147,275'Corticotropin releasing factor receptor 1-deficient mice'20006,023,011'Corticotropin-releasing factor overproducing transgenic mice'20005,910,428'Brain-derived membrane-associated CRF binding proteins'19995,885,794'Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-.beta. superfamily'19995,844,080'CRF binding protein'19985,744,450'GnRH analogs'19985,733,790'CRF binding protein antibodies and assays using same'19985,728,545'Cloning and recombinant production of CRF receptor (S)'19985,587,462'Brain-derived membrane-associated CRF binding proteins'19965,530,095'Peptides of melanin concentrating hormone precursor'19965,510,458'CRF antagonists'19965,493,006'Cyclic CRF analogs'19965,464,757'DNA encoding CRF binding protein'19955,449,766'DNA encoding NEI and NGE peptides'19955,439,885'CRF analogs'19955,296,468'GnRH analogs'19945,278,146'CRF analogs'19945,262,519'GRF analogs XI'19935,245,009'CRF antagonists'19935,235,036'CRF analogs'19935,169,932'GnRH analogs'19925,132,111'CRF analog conjugates'19925,112,809'CRF analogs'19925,109,111'CRF antagonists'19925,098,995'GRF Analogs VIIA'19925,064,939'Cyclic GnRH antagonists'19915,049,655'Melanin-concentrating hormones'19915,043,322'Cyclic GRF analogs'19915,032,507'Potentiation of erythropoiesis'19915,015,729'Ovine inhibin'19915,002,931'GRF analogs VII'19914,973,577'FSH-releasing peptides'19904,864,019'Antibodies to inhibin and conjugates produced therefrom'19894,843,064'GRF analogs V'19894,784,987'GRF analogs VI'19884,740,500'GnRH antagonists VIII'19884,737,578'Human inhibin'19884,728,726'GRF analogs IIIb'19884,703,035'Human pancreatic GRF amidated fragments'19874,689,396'GnRH antagonists V'19874,677,193'Peptides containing an aliphatic-aromatic ketone side chain'19874,661,472'GnRH antagonists IX'19874,652,550'GnRH antagonists VII'19874,628,043'Hypothalamic GRF agonists'19864,626,523'GRF analogs II'19864,619,914'GNRH antagonists IIIB'19864,605,642'CRF antagonists'19864,595,676'Rat hypothalamic GRF'19864,594,329'CRF analogs'19864,569,927'GnRH Antagonists IV'19864,565,804'GnRH Antagonists VI'19864,563,352'Human pancreatic GRF'19864,530,838'Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals'19854,529,595'GRF Analogs'19854,528,190'GRF Analogs IV'19854,518,586'GRF Analogs III'19854,489,061'Treatment of male mammals'19844,489,163'rCRF and analogs'19844,444,759'GnRH Antagonists II'19844,443,368'Peptides affecting gonadal function'19844,428,942'Analogs of somatostatin'19844,415,558'CRF And analogs'19834,410,514'GnRH Agonists'19834,409,208'GnRH antagonists'19834,393,050'Analogs of extended N-terminal somatostatin'19834,386,074'LRF Antagonists'19834,382,922'Peptides affecting gonadal function'19834,377,574'Contraceptive treatment of male mammals'19834,372,884'Pharmaceutically active peptides'19834,307,083'LRF Antagonists'19814,292,313'LRF Antagonists'19814,261,887'Peptide compositions'1981RE030548'Peptides which effect release of hormones'19814,244,946'Water-soluble peptides affecting gonadal function'19814,218,439'Peptide which inhibits gonadal function'19804,215,038'Peptides which inhibit gonadal function'19804,211,693'Peptides with para-substituted phenylalanine'19804,207,311'Peptides having analgesic and thermoregulative properties'19804,133,782'Somatostatin analogs with dissociated biological activities'19794,105,603'Peptides which effect release of hormones'19784,072,668'LH-RH Analogs'1978

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1978–2011Patents assigned to SALK INST FOR BIOLOGICAL STUDI (88)· patent assignee history
1978–2017Based in La Jolla, CA, US· patent location history
1985–2006Based in LaJolla, CA, US· patent location history
1995–1998Patents assigned to UNIV READING (4)· patent assignee history
2000–2017Patents assigned to RES DEV FOUNDATION (27)· patent assignee history
2011–2013Patents assigned to GULYAS JOZSEF (2)· patent assignee history
2011–2013Patents assigned to KUNITAKE KOICHI S (2)· patent assignee history
2014Based in Carson City, NV, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SALK INST FOR BIOLOGICAL STUDI881978–2011
RES DEV FOUNDATION272000–2017
UNIV READING41995–1998
GULYAS JOZSEF22011–2013
KUNITAKE KOICHI S22011–2013
Locations
LocationPatentsSpan
La Jolla, California, US1111978–2017
LaJolla, California, US41985–2006
Carson City, NV, US12014